Shares of Bristol-Myers Squibb Co. jumped by as much as 5.35% to $62.97 in New York trading Thursday as traders applauded a late-Wednesday court ruling that upheld patents on the blockbuster blood-thinner Eliquis.
Bristol-Myers and Pfizer Inc., which share profits from sales of the drug, proved that generic-drug makers Sigmapharm Laboratories LLC, Unichem Laboratories Ltd. and Sunshine Lake Pharma Co. Ltd. would infringe valid patents, a federal judge in Wilmington, Delaware, said.
The three generic-drug makers can’t launch their copycat versions of Eliquis until 2031, said Susan Francis, a spokesperson for Bristol-Myers. Based on settlement agreements previously reached ...
